The goal is to deliver greater value to customers, doctors, and the broader healthcare ecosystem
Pegozafermin offers a distinct mechanism of action with potential for enhanced efficacy and tolerability and opportunities for combination development with incretins
Funding supports development of first-in-class pan-ROCK inhibitor ROC-101 through Phase 2a clinical testing
This predictive technology empowers people with diabetes to take preventive action before complications arise
The Phase Ib MAD study is a randomized, double-blind, placebo-controlled trial conducted in the United States
Merck opens first climate-neutral manufacturing facility in Ireland
The TULIP-SC trial investigated the efficacy and safety of subcutaneous Saphnelo
Wegovy achieved significant weight loss with one in three study participants losing 20% or more body weight
The lab will facilitate the development of herbal and natural-based solutions
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
